Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Knee replacement pain study aims to cut chronic pain risk

NCT ID NCT03998813

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to manage pain after total knee replacement: a continuous nerve block using a catheter near the femoral triangle versus tissue infiltration with a local anesthetic. The goal is to see which method better prevents long-term chronic pain and improves knee function. About 287 adults scheduled for knee replacement will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ropivacaine
What this could lead to
If successful, this could point to a better way to manage pain after knee replacement, reducing the chance of long-term chronic pain and improving recovery.
What could go wrong
This is a single-center study, and results may not apply to all patients. The two techniques may show little difference, or one may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

287 people

The number who actually took part.

Started

Sep 2020

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient; * Placement of unilateral tricompartmental knee prosthesis for gonarthrosis; * ASA score between I and III ; * Nonseptic scheduled surgery; * Knee replacement scheduled on one of the first 3 days of the week (Monday to Wednesday included) in order to benefit from a homogeneous postoperative physical therapy; * Able to understand the protocol; * Having agreed to participate in the study and having given express oral consent; * Affiliated with a social security system; * Possibility of being followed as part of the protocol. Exclusion Criteria: * Age \>= 86 years old; * BMI \> 35 ; * Revision of knee replacement; * Symptomatic contralateral osteoarthritis; * Anterior of surgery on the operated knee (excluding arthroscopy and meniscectomy); * Vascular surgery on the femoral vessels on the operated side; * Concept of diffuse polyalgia syndrome (fibromyalgia); * Documented neuropathy of the lower limb; * Localized infection at the catheter puncture site (femoral triangle); * Known allergy to Ropivacaine; * Renal insufficiency (Clearance - CKD-EPI formula - creatinine \<30 ml/min) and/or severe hepatic insufficiency (prothrombin blood level \<50%) ; * Inflammatory rheumatic disease (rheumatoid arthritis, ankylosing spondylitis...) ; * Patients on immunosuppressive or systemically administered corticosteroid therapy; * Daily use of level II or III analgesics for more than one month pre-operatively; * Known intolerance to tier III analgesics; * Allergy or contraindications to standard treatments administered per and postoperatively (paracetamol, NSAIDs); * Patient undergoing knee surgery in the year prior to inclusion and participating in the study; * Patients who do not cooperate or do not understand French, difficulties in understanding and evaluating the pain score, preoperative cognitive dysfunction making the interview unreliable; * Patient under guardianship, curators, deprivation of liberty; * Patient already engaged in another interventional clinical study (category 1); * Pregnant or breastfeeding women, or women in a position to procreate who refuse an effective means of contraception; * Refusal to participate; * Inability to understand the protocol and its requirements, and/or to give express oral consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gonarthrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Départemental Vendée

    La Roche-sur-Yon, 85925, France

  • Centre Hospitalier de Béthune Beuvry

    Béthune, France

  • Clinique Victor PAUCHET

    Amiens, France

  • Hôpital Privé Sévigné

    Rennes, France

  • Hôpital des Diaconesses Croix Saint Simon

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.